Comparative Pharmacology
Head-to-head clinical analysis: LORAZEPAM INTENSOL versus NAYZILAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORAZEPAM INTENSOL versus NAYZILAM.
LORAZEPAM INTENSOL vs NAYZILAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Nayzilam (midazolam) is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion conductance, neuronal hyperpolarization, and inhibition of neuronal activity.
0.5-2 mg orally every 6-8 hours as needed. Maximum 4 mg/day.
5 mg intranasally as a single dose; may repeat once after 10 minutes if needed. Maximum 10 mg per episode.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in elderly (15-20 hours) and patients with hepatic impairment (up to 30-40 hours).
Terminal elimination half-life of midazolam is 1.5–2.5 hours, but for NAYZILAM (midazolam nasal spray) the effective half-life for anticonvulsant effect is approximately 2–3 hours due to prolonged absorption; clinical context: used for seizure clusters, duration of effect may persist for 4–6 hours.
Renal excretion of glucuronide conjugates; <1% unchanged drug excreted renally. Fecal elimination accounts for approximately 10% of administered dose.
Renal excretion as metabolites (primarily glucuronide conjugates) and unchanged drug; approximately 15% recovered in urine as unchanged midazolam, with the remainder as metabolites; <1% excreted in feces via biliary elimination.
Category D/X
Category C
Benzodiazepine
Benzodiazepine